Royal Bank of Canada
PROF

Royal Bank of Canada’s Profound Medical PROF Stock Holding History

Royal Bank of Canada’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.19M Buy
493,060
+19,842
+4% +$137K ﹤0.01% 2745
2025
Q4 		$3.73M Sell
473,218
-12,702
-3% -$81.6K ﹤0.01% 2661
2025
Q3 		$2.38M Buy
485,920
+26,001
+6% +$133K ﹤0.01% 3257
2025
Q2 		$2.71M Buy
459,919
+23,922
+5% +$126K ﹤0.01% 3050
2025
Q1 		$2.54M Buy
435,997
+14,795
+4% +$102K ﹤0.01% 2773
2024
Q4 		$3.16M Buy
421,202
+19,877
+5% +$153K ﹤0.01% 2678
2024
Q3 		$3.19M Buy
401,325
+96
+0% +$867 ﹤0.01% 2637
2024
Q2 		$3.37M Buy
401,229
+1,103
+0.3% +$8.89K ﹤0.01% 2503
2024
Q1 		$3.41M Sell
400,126
-33
-0% -$275 ﹤0.01% 2490
2023
Q4 		$3.4M Sell
400,159
-1,674
-0.4% -$15.9K ﹤0.01% 2585
2023
Q3 		$4.1M Buy
401,833
+1,153
+0.3% +$12K ﹤0.01% 2248
2023
Q2 		$5.21M Sell
400,680
-314
-0.1% -$3.9K ﹤0.01% 2069
2023
Q1 		$3.73M Buy
400,994
+1,374
+0.3% +$15.9K ﹤0.01% 2313
2022
Q4 		$4.35M Buy
399,620
+13,000
+3% +$70.9K ﹤0.01% 2251
2022
Q3 		$1.56M Sell
386,620
-386
-0.1% -$2.6K ﹤0.01% 3053
2022
Q2 		$2.82M Buy
387,006
+65,305
+20% +$516K ﹤0.01% 2574
2022
Q1 		$2.9M Buy
321,701
+59,998
+23% +$578K ﹤0.01% 2718
2021
Q4 		$2.94M Buy
261,703
+8,927
+4% +$111K ﹤0.01% 2824
2021
Q3 		$3.7M Buy
252,776
+846
+0.3% +$12.9K ﹤0.01% 2555
2021
Q2 		$4.12M Buy
251,930
+245,850
+4,044% +$4.57M ﹤0.01% 2452
2021
Q1 		$122K Sell
6,080
-2,234
-27% -$53.6K ﹤0.01% 5324
2020
Q4 		$171K Buy
8,314
+2,453
+42% +$45.1K ﹤0.01% 4965
2020
Q3 		$103K Buy
5,861
+366
+7% +$5.82K ﹤0.01% 4960
2020
Q2 		$93K Buy
5,495
+1,141
+26% +$14.4K ﹤0.01% 4894
2020
Q1 		$43K Buy
4,354
+654
+18% +$8.48K ﹤0.01% 5232
2019
Q4 		$40K Buy
+3,700
New +$34.1K ﹤0.01% 5544

Other funds holding PROF

Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GA
Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
ZCP
Z3 Capital Partners Richmond, Virginia $395M AUM
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Royal Bank of Canada's PROF Position: Q1 2026 in Review

Royal Bank of Canada increased its Profound Medical (PROF) stake by 4.2% in Q1 2026, buying an estimated $137K and bringing the position to 493,060 shares worth $3.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2745.

Royal Bank of Canada first reported a position in PROF in Q4 2019 and has held it in 26 quarters since. The position peaked at $5.21M in Q2 2023. 57 funds tracked by Wall St. Rank hold PROF as of Q1 2026.

  • Royal Bank of Canada held 493,060 shares of Profound Medical worth $3.19M as of Q1 2026.
  • Royal Bank of Canada bought 19,842 Profound Medical shares in Q1 2026, an estimated $137K.
  • Profound Medical made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #2745 holding.
  • Royal Bank of Canada first reported a position in Profound Medical in Q4 2019 and has held it in 26 quarters since.
  • Royal Bank of Canada's Profound Medical position peaked at $5.21M in Q2 2023.
  • 57 funds tracked by Wall St. Rank held Profound Medical as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.